FMP

FMP

Enter

TBIO - Telesis Bio, In...

photo-url-https://images.financialmodelingprep.com/symbol/TBIO.png

Telesis Bio, Inc.

TBIO

OTC

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

0.75 USD

-0.25 (-33.33%)

Historical Prices

From:

To:

0.750.7520.7540.7560.7580.7612:39 PM12:55 PM01:35 PM02:40 PM03:09 PM

About

ceo

Mr. Eric Esser

sector

Healthcare

industry

Medical - Devices

exchange

OTC

Description

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop r...

CIK

0001693415

ISIN

US1920031010

CUSIP

89374L104

Address

29 Hartwell Ave

Phone

16179457361

Country

US

Employee

39

IPO Date

Jun 18, 2021

Financial Statement

-20M-15M-10M-5M05M10M2023 Q32023 Q42024 Q12024 Q22024 Q3RevenueNet Income

Earnings

-100-80-60-40-2002023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

TBIO Financial Summary

CIK

0001693415

Exchange

OTC

Industry

Medical - Devices

Sector

Healthcare

CUSIP

89374L104

ISIN

US1920031010

Country

US

Price

0.75

Beta

1.57

Volume Avg.

5.48k

Market Cap

1.33M

Shares

-

52-Week

0.25-8.352

DCF

43.02

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.02

P/B

-

Website

https://codexdna.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest TBIO News

InvestorPlace

Feb 23, 2024

Why Is Telesis Bio (TBIO) Stock Up 29% Today?

Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with some 7.4 million shares changing hands as of this writing.

GlobeNewsWire

Aug 3, 2023

Telesis Bio to Report Second Quarter Financial Results on Th...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

GlobeNewsWire

Jun 8, 2023

Telesis Bio to Present at Jefferies Healthcare Conference 20...

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.

GlobeNewsWire

Jun 6, 2023

Telesis Bio to Present at Antibody Engineering and Therapeut...

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery

GlobeNewsWire

May 23, 2023

Telesis Bio to Present at SynBioBeta 2023

Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery

GlobeNewsWire

May 15, 2023

Telesis Bio to Present at Protein Engineering Summit (PEGS B...

Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications

Zacks Investment Research

May 11, 2023

Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates

Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.

GlobeNewsWire

Apr 27, 2023

Telesis Bio to Report First Quarter Financial Results on Thu...

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep